89 related articles for article (PubMed ID: 15718346)
1. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Hofer MD; Rubin MA
J Clin Oncol; 2005 Feb; 23(6):1332-3; author reply 1333-4. PubMed ID: 15718346
[No Abstract] [Full Text] [Related]
2. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
3. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
Mathew P; Fidler IJ; Logothetis CJ
Semin Oncol; 2004 Apr; 31(2 Suppl 6):24-9. PubMed ID: 15176001
[TBL] [Abstract][Full Text] [Related]
4. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Altundag K; Altundag O; Morandi P; Gunduz M
Urology; 2005 Jan; 65(1):211-2; author reply 212. PubMed ID: 15667906
[No Abstract] [Full Text] [Related]
7. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Chew HK; Barlow WE; Albain K; Lew D; Gown A; Hayes DF; Gralow J; Hortobagyi GN; Livingston R
Clin Breast Cancer; 2008 Dec; 8(6):511-5. PubMed ID: 19073506
[TBL] [Abstract][Full Text] [Related]
8. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
Mathew P; Wen S; Morita S; Thall PF
J Interferon Cytokine Res; 2011 Jul; 31(7):539-44. PubMed ID: 21323568
[TBL] [Abstract][Full Text] [Related]
9. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
11. Rationale for combination use of targeted agents in ovarian cancer: do we have one?
Coleman RL; Kohn EC
Cancer; 2008 Aug; 113(4):665-7. PubMed ID: 18623195
[No Abstract] [Full Text] [Related]
12. [Promising new treatment options for metastatic androgen-independent prostate cancer].
Tan W
Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565
[TBL] [Abstract][Full Text] [Related]
13. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Huang CH; Williamson SK; Van Veldhuizen PJ; Hsueh CT; Allen A; Tawfik O; Wick J; Smith H; Uypeckcuat AM; Mayo M; Kelly K
J Thorac Oncol; 2011 Feb; 6(2):372-7. PubMed ID: 21178640
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
Yardley DA; Burris HA; Markus T; Spigel DR; Greco FA; Mainwaring M; Waterhouse DM; Webb CD; Hainsworth JD
Clin Breast Cancer; 2009 Nov; 9(4):237-42. PubMed ID: 19933079
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
